child |
TDLo |
intravenous |
18750mg/kg/5D (18750mg/kg) |
BRAIN AND COVERINGS: ENCEPHALITIS
SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE |
Cancer Treatment Reports. Vol. 70, Pg. 1225, 1986. |
man |
TDLo |
intravenous |
11655mg/kg/5D (11655mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE
SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
Cancer Treatment Reports. Vol. 70, Pg. 1449, 1986. |
man |
TDLo |
intravenous |
17760mg/kg/5D (17760mg/kg) |
BRAIN AND COVERINGS: DEMYELINATION
BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"
BEHAVIORAL: COMA |
Cancer Treatment Reports. Vol. 70, Pg. 1225, 1986. |
mouse |
LD50 |
intravenous |
1236mg/kg (1236mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
National Technical Information Service. Vol. PB83-195685, |
women |
LDLo |
intravenous |
14245mg/kg/5D (14245mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE
BEHAVIORAL: EXCITEMENT
SKIN AND APPENDAGES (SKIN): SWEATING: OTHER |
Cancer Treatment Reports. Vol. 70, Pg. 1449, 1986. |
women |
TDLo |
intravenous |
23125mg/kg/5D (23125mg/kg) |
BRAIN AND COVERINGS: ENCEPHALITIS
SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
Cancer Treatment Reports. Vol. 70, Pg. 1225, 1986 |